Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

BACKGROUND: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Hist...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ther Adv Med Oncol
Главные авторы: Avallone, Antonio, Piccirillo, Maria Carmela, Di Gennaro, Elena, Romano, Carmela, Calabrese, Filomena, Roca, Maria Serena, Tatangelo, Fabiana, Granata, Vincenza, Cassata, Antonio, Cavalcanti, Ernesta, Maurea, Nicola, Maiolino, Piera, Silvestro, Lucrezia, De Stefano, Alfonso, Giuliani, Francesco, Rosati, Gerardo, Tamburini, Emiliano, Aprea, Pasquale, Vicario, Valeria, Nappi, Anna, Vitagliano, Carlo, Casaretti, Rossana, Leone, Alessandra, Petrillo, Antonella, Botti, Gerardo, Delrio, Paolo, Izzo, Francesco, Perrone, Francesco, Budillon, Alfredo
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2020
Предметы:
Study Protocol
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425244/
https://ncbi.nlm.nih.gov/pubmed/32849914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920929589
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы